Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BP 294

Drug Profile

BP 294

Alternative Names: FUB 94

Latest Information Update: 28 Nov 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bioprojet
  • Developer Bioprojet; INSERM
  • Class Analgesics; Anti-inflammatories; Antiasthmatics; Antiulcers; Imidazoles
  • Mechanism of Action Histamine H3 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma; Inflammation; Pain; Peptic ulcer

Most Recent Events

  • 15 May 2001 A study has been added to the Pain pharmacodynamics section
  • 08 Feb 2000 A study has been added to the Peptic Ulcer disease pharmacodynamics section
  • 22 Jul 1997 Preclinical development for Inflammation in France (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top